Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?
The objectives of this study were to compare the risk of venous thromboembolism (VTE), bleeding, surgical site infection, and mortality in patients receiving aspirin or guideline-approved VTE prophylactic therapies (warfarin, low-molecular-weight heparins, synthetic pentasaccharides) in total knee arthroplasty (TKA). We analyzed clinical and administrative data from 93,840 patients who underwent primary TKA at 307 US hospitals over a 24-month period. Fifty-one thousand nine hundred twenty-three (55%) patients received warfarin, 37,198 (40%) received injectable agents, and 4719 (5%) received aspirin. After adjustment for patient and hospital factors, patients who received aspirin VTE prophylaxis (VTEP) had lower odds for thromboembolism compared to warfarin patients but with similar odds compared with injectable VTEP; there were no differences in risk of bleeding, infection, or mortality after adjustment. Our results suggest that aspirin, when used in conjunction with other clinical care protocols, may be effective VTEP for certain TKA patients.
Bozic
Kevin J
KJ
Department of Orthopedic Surgery and Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, California 94143-0728, USA.
Vail
Thomas P
TP
Pekow
Penelope S
PS
Maselli
Judith H
JH
Lindenauer
Peter K
PK
Auerbach
Andrew D
AD
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D019645:Arthroplasty, Replacement, Knee; D001241:Aspirin / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use; D011183:Postoperative Complications; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D011134:Polysaccharides; D014859:Warfarin; D000077425:Fondaparinux; D001241:Aspirin
Surg Technol Int. 2004;13:231-8
15744695
Chest. 2005 Nov;128(5):3364-71
16304285
J Arthroplasty. 2007 Apr;22(3):317-24
17400085
Lancet. 2000 Apr 15;355(9212):1295-302
10776741
Med Care. 2000 Aug;38(8):868-76
10929998
Chest. 2004 Sep;126(3 Suppl):338S-400S
15383478
Clin Orthop Relat Res. 2006 Nov;452:175-80
16957642
Am J Orthop (Belle Mead NJ). 2006 Jan;35(1):24-9
16475420
Emerg Infect Dis. 2001 Mar-Apr;7(2):212-6
11294709
Med Care. 2000 Aug;38(8):785-95
10929991
J Surg Orthop Adv. 2006 Summer;15(2):79-85
16919198
J Arthroplasty. 2001 Apr;16(3):293-300
11307125
J Bone Joint Surg Am. 1996 Jun;78(6):826-34
8666599
Comput Aided Surg. 2007 May;12(3):189-93
17538792
Rheum Dis Clin North Am. 2007 Feb;33(1):71-86
17367693
Med Care. 1998 Jan;36(1):8-27
9431328
Clin Orthop Relat Res. 1996 Mar;(324):251-8
8595765
Am J Orthop (Belle Mead NJ). 2006 Jul;35(7 Suppl):4-6
16927646
J Bone Joint Surg Am. 1976 Oct;58(7):928-32
977623
N Engl J Med. 1977 Dec 8;297(23):1246-9
335247
J Pak Med Assoc. 2006 Feb;56(2):72-5
16555639
Ann Pharmacother. 2006 Nov;40(11):2074
17062836
Semin Thromb Hemost. 1991;17 Suppl 3:304-12
1754886
Curr Med Res Opin. 2005 Oct;21(10):1583-94
16238898
J Knee Surg. 2006 Apr;19(2):137-43
16642893
J Bone Joint Surg Am. 2006 Feb;88(2):282-9
16452738
Br Med J. 1980 Feb 23;280(6213):514-7
6989432
Reg Anesth Pain Med. 2006 Sep-Oct;31(5):480
16952824
Medsurg Nurs. 2007 Jun;16(3):151-4; quiz 155
17849920
J Arthroplasty. 2007 Jan;22(1):20-5
17197304
JAMA. 2003 Nov 26;290(20):2685-92
14645310
J Bone Joint Surg Br. 2000 Aug;82(6):795-800
10990299
Clin Orthop Relat Res. 2006 Nov;452:117-22
16957640
Thromb Res. 2006;118(2):253-62
16081144